cIAP-1与XIAP在卵巢癌组织中的表达及其与预后的关系

目的探索细胞凋亡抑制蛋白(cIAP)家族中的cIAP-1、XIAP在卵巢癌组织中的表达及与预后的关系.方法选取2004-2009年在解放军总医院行卵巢癌肿瘤细胞减灭术、术前经过新辅助化疗且术后病理证实为卵巢浆液性癌患者99例,统计发病时是否绝经、新辅助化疗用药、病理分级分期等参数,电话随访无瘤生存期及总生存期,取病理标本石蜡切片行免疫组化,观察cIAP-1与XIAP的表达,并分析其与各参数的关系.结果 cIAP-1的表达水平与卵巢癌分级(P=0.034)、新辅助化疗(P=0.035)具有相关性,而与是否绝经无关(P=0.161);XIAP的表达水平与上述均无明显相关性(分别为P=0.230, P=0.192,P=0.560).cIAP-1高表达与低表达患者总生存期之间差异有统计学意义(P=0.014),而XIAP的表达水平的高低在总生存期上差异无统计学意义(P=0.33);尚未发现cIAP-1和XIAP的表达水平与患者无瘤生存期有显著关系(P=0.091, P=0.181).结论接受新辅助化疗后,患者cIAP-1表达水平与肿瘤分级、总生存期具有相关性,可作为卵巢癌预后检测指标.

Expression of cIAP-1 and XIAP in ovarian cancer tissue and its relation with prognosis of ovarian cancer patients

Objective To study the expression of cIAP-1 and XIAP in ovarian cancer tissue and its relation with prognosis of ovarian cancer patients.Methods Ninety-nine patients with pathology-confirmed serous ovarian cancer who were treated with neo-adjuvant chemotherapy before they underwent tumor cell reductive operation in our hospital from 2004-2009 were included in this study.Parameters of menopause,drugs used in neo-adjuvant chemotherapy,pathology classification and staging,tumor-free survival time and overall survival time were recorded.Expression of cIAP-1 and XIAP in paraffin tissue sample sections was detected with immunohistochemical staining and its relation with the parameters was analyzed.Results The cIAP1 expression level was correlated with tumor grade(P=0.034) and neo-adjuvant chemotherapy(P=0.035),but not with menopause(P=0.161).The CIAP expression level was not significantly correlated with the above parameters(P=0.230,0.192,0.560).A significant difference was found in overall survival time of patients with a high or low cIAP-1 and XIAP expression level(P=0.014).However,no significant difference was observed in overall survival time of patients with a high or low expression XIAP level(P=0.33).No significant correlation was found between tumor-free survival time and cIAP-1 and XIAP expression level(P=0.091,P=0.181).Conclusion The cIAP-1 expression level is correlated with tumor grade and overall survival time in patients with ovarian cancer after neo-adjuvant chemotherapy and can be used as an indication of their prognosis.